<i>In vivo</i> dose response and efficacy of the ß-lactamase inhibitor, durlobactam, in combination with sulbactam against the <i>Acinetobacter baumannii-calcoaceticus</i> complex.

O'Donnell, John; Tanudra, Angela; Chen, April; Newman, Joseph; McLeod, Sarah M; Tommasi, Rubén

In vivo dose response and efficacy of the ß-lactamase inhibitor, durlobactam, in combination with sulbactam against the Acinetobacter baumannii-calcoaceticus complex.

O'Donnell, John; Tanudra, Angela; Chen, April; Newman, Joseph; McLeod, Sarah M; Tommasi, Rubén.

Afiliação

O'Donnell J; Entasis Therapeutics Inc. , Waltham, Massachusetts, USA.
Tanudra A; Entasis Therapeutics Inc. , Waltham, Massachusetts, USA.
Chen A; Entasis Therapeutics Inc. , Waltham, Massachusetts, USA.
Newman J; Omega Therapeutics , Watertown, Massachusetts, USA.
McLeod SM; Entasis Therapeutics Inc. , Waltham, Massachusetts, USA.
Tommasi R; Entasis Therapeutics Inc. , Waltham, Massachusetts, USA.

Antimicrob Agents Chemother ; 68(1): e0080023, 2024 Jan 10.

Article em En | MEDLINE | ID: mdl-38092671

Assuntos

Acinetobacter baumannii; Sulbactam; Sulbactam/uso terapêutico; Inibidores de beta-Lactamases/farmacologia; Inibidores de beta-Lactamases/uso terapêutico; Antibacterianos/uso terapêutico; Testes de Sensibilidade Microbiana

Palavras-chave

durlobactam; pharmacodynamics; pharmacokinetics; sulbactam

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sulbactam / Acinetobacter baumannii Idioma: En Revista: Antimicrob Agents Chemother Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google